Enrolling By Invitation NCT07450664
Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome
An Observational Study of VYKAT™ XR (Diazoxide Choline Extended-Release Tablets) in Patients With Prader-Willi Syndrome (PWS)
Sponsor: Soleno Therapeutics, Inc.
Conditions
Prader-Willi Syndrome
Interventions
VYKAT XR
Updated 1 time since 2026 Last updated: Mar 1, 2026 Started: Nov 26, 2025 Primary completion: Mar 31, 2028 Completion: Mar 2, 2028
Listed as NCT07450664, this observational or N/A phase trial focuses on Prader-Willi Syndrome and remains ongoing. Sponsored by Soleno Therapeutics, Inc., it has been updated 1 time since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
1 version recorded Enrolling By Invitation
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Soleno Therapeutics, Inc.
Data source: Soleno Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Indianapolis, United States
- • Lansing, United States